Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase II trial (Trial 1008) in 239 patients undergoing excision of benign head and neck
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury